Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration.
SGLT2
diabetes
neointima formation
restenosis
vascular remodeling
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
05
2022
accepted:
25
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Empagliflozin, an inhibitor of the sodium glucose co-transporter 2 (SGLT2) and developed as an anti-diabetic agent exerts additional beneficial effects on heart failure outcomes. However, the effect of empagliflozin on vascular cell function and vascular remodeling processes remains largely elusive. Immunocytochemistry and immunoblotting revealed SGLT2 to be expressed in human smooth muscle (SMC) and endothelial cells (EC) as well as in murine femoral arteries. Empagliflozin significantly reduces serum-induced proliferation and migration of SMCs
Sections du résumé
Background
UNASSIGNED
Empagliflozin, an inhibitor of the sodium glucose co-transporter 2 (SGLT2) and developed as an anti-diabetic agent exerts additional beneficial effects on heart failure outcomes. However, the effect of empagliflozin on vascular cell function and vascular remodeling processes remains largely elusive.
Methods/Results
UNASSIGNED
Immunocytochemistry and immunoblotting revealed SGLT2 to be expressed in human smooth muscle (SMC) and endothelial cells (EC) as well as in murine femoral arteries.
Conclusion
UNASSIGNED
Empagliflozin significantly reduces serum-induced proliferation and migration of SMCs
Identifiants
pubmed: 36017090
doi: 10.3389/fcvm.2022.956041
pmc: PMC9396257
doi:
Types de publication
Journal Article
Langues
eng
Pagination
956041Informations de copyright
Copyright © 2022 Dutzmann, Bode, Kalies, Korte, Knöpp, Kloss, Sirisko, Pilowski, Koch, Schenk, Daniel, Bauersachs and Sedding.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Redox Biol. 2020 May;32:101527
pubmed: 32278282
J Biol Chem. 2004 Jun 18;279(25):26274-9
pubmed: 15087458
Front Physiol. 2018 Nov 21;9:1575
pubmed: 30519189
JAMA Cardiol. 2017 Sep 1;2(9):1025-1029
pubmed: 28768320
Int J Cardiol. 2017 Jul 1;238:79-91
pubmed: 28433555
Ann Transl Med. 2021 Apr;9(8):627
pubmed: 33987325
Biomed Pharmacother. 2020 Aug;128:110271
pubmed: 32450527
Cell Signal. 2021 Jan;77:109825
pubmed: 33160017
Cardiovasc Pathol. 2020 Nov - Dec;49:107230
pubmed: 32585603
Biochem Biophys Res Commun. 2013 Sep 20;439(2):235-40
pubmed: 23973488
Nat Med. 2002 Nov;8(11):1249-56
pubmed: 12411952
Can J Cardiol. 2021 Apr;37(4):531-546
pubmed: 33827756
Int J Biochem Cell Biol. 2015 Dec;69:173-82
pubmed: 26494002
Cardiovasc Res. 2017 Nov 01;113(13):1653-1663
pubmed: 29088375
Am J Respir Crit Care Med. 2018 Sep 15;198(6):788-802
pubmed: 29664678
Circulation. 2022 May 3;145(18):e895-e1032
pubmed: 35363499
Heart Vessels. 2020 Oct;35(10):1378-1389
pubmed: 32399662
PLoS One. 2017 Sep 19;12(9):e0184888
pubmed: 28926607
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Curr Protoc Pharmacol. 2015 Sep 01;70:5.47.1-5.47.20
pubmed: 26331889
J Clin Invest. 2008 Oct;118(10):3343-54
pubmed: 18769630
Biochem Biophys Res Commun. 2004 Dec 10;325(2):395-400
pubmed: 15530405
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Diabetologia. 2017 Mar;60(3):395-398
pubmed: 28074254
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Regul Pept. 2001 Jun 15;99(2-3):87-92
pubmed: 11384769
Circulation. 2017 Oct 17;136(16):1459-1461
pubmed: 29038205
Eur J Heart Fail. 2017 Nov;19(11):1390-1400
pubmed: 28836359
Front Biosci. 2008 May 01;13:3786-92
pubmed: 18508473
J Clin Invest. 2020 Jan 2;130(1):94-107
pubmed: 31738185
Eur J Heart Fail. 2017 Jan;19(1):43-53
pubmed: 27653447
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Nature. 2012 Aug 16;488(7411):394-8
pubmed: 22810587
Cardiovasc Res. 2021 Feb 22;117(3):850-862
pubmed: 32353113
Circ Cardiovasc Interv. 2019 Aug;12(8):e007023
pubmed: 31345066
Circulation. 2010 May 25;121(20):2192-9
pubmed: 20458015
Biochem Biophys Rep. 2019 Apr 19;18:100640
pubmed: 31032431
Cardiovasc Res. 2010 Jul 1;87(1):156-65
pubmed: 20176814